成都康弘药业集团股份有限公司 （一）公司所遵循的国家和地方的现行有关法律、法规和制度无 重大变化； （二）公司主要经营所在地及业务涉及地区的社会经济环境无重 大变化； 二〇二五年度财务预算报告 （三）公司所处行业形势、市场行情、主要产品和原料的市场价 格和供求关系无重大变化； 特别提示：本预算为公司二〇二五年度经营计划的内部管理控制 指标，不代表公司对二〇二五年度的盈利预测，能否实现取决于内外 部环境变化等多种因素，存在较大的不确定性，提请投资者特别注意！ 一、预算编制说明 根据《公司章程》的相关规定，公司以二〇二四年度经审计的经 营业绩为基础，结合公司战略发展目标及二〇二五年市场营销计划、 生产经营计划等，经过慎重分析研究，编制了《二〇二五年度财务预 算报告》。 二、预算编制基本假设 （四）按现行的国家主要税率、汇率及银行信贷利率； （五）无其他不可抗力及不可预见因素造成的重大不利影响。 三、二〇二五年度主要预算指标 （五）强化财务管理，加强成本控制分析、预算执行、资金运行 情况监管等方面的工作，建立成本控制、预算执行、资金运行的预警 机制，降低财务风险，及时发现问题并持续改进，保证财务指标的实 现。 成都 ...

成都康弘药业集团股份有限公司 董事会审计委员会对会计师事务所 2024 年度 履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》和成都康弘药业集团股 份有限公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作细则》 等规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。 现将董事会审计委员会对会计师事务所 2024 年度履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 根据公司《董事会审计委员会工作细则》等有关规定，审计委员会对会计师 事务所履行监督职责的情况如下： （一）2024 年 4 月 24 日，公司第八届董事会审计委员会审议通过了《关于 聘请二○二四年度审计机构的议案》，公司董事会审计委员会已对信永中和有 关资格证照、相关信息和诚信记录进行了认真核查，认为其在执业过程中坚持 独立审计准则，遵守职业道德规范，按照中国注册会计师审计准则执行审计工 作，相关审计意见客观、公正、公允地反映公司财务状况、经营成果，切实履 行审计机构应尽的职责。为保证审计工作的连续性，同意 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-018 成都康弘药业集团股份有限公司 关于召开二〇二四年度股东会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东会届次：二〇二四年度股东会。 （二）股东会的召集人：成都康弘药业集团股份有限公司（以下 简称"公司"）董事会。 （三）会议召开的合法、合规性：公司第八届董事会第十次会议 审议通过了《关于召开二〇二四年度股东会的议案》，决定召开公司 二〇二四年度股东会。本次会议的召集、召开符合有关法律、行政法 规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》 等的规定。 （四）会议召开的日期、时间 1、现场会议日期与时间：2025年5月21日（星期三）14:00； 2、网络投票日期与时间：2025年5月21日（星期三），其中：通 过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月21 日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为2025年5月21日9:15-15 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-011 成都康弘药业集团股份有限公司 第八届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届监 事会第十次会议于 2025 年 4 月 25 日在公司会议室以现场方式召开。 会议通知于 2025 年 4 月 15 日以书面、传真或电子邮件等形式向所有 监事发出。本次监事会应到监事 3 名，实到监事 3 名，会议由监事会 主席龚文贤先生主持，公司董事会秘书列席会议。本次会议的召开符 合《中华人民共和国公司法》和《成都康弘药业集团股份有限公司章 程》的有关规定。 二、监事会会议审议情况 1. 会议以3票同意，0票反对，0票弃权审议通过了《二○二四年 度监事会工作报告》。 经审查，监事会认为：本报告如实反映了二〇二四年监事会的履 职情况，同意通过该报告，并表示将继续严格按照有关法律法规、监 管要求及《公司章程》的规定，恪尽职守，勤勉尽责，进一步促进公 1 / 6 司的规范运作。 《二〇二四年度监事会工 ...

一、董事会会议召开情况 证券代码：002773 证券简称：康弘药业 公告编号：2025-010 成都康弘药业集团股份有限公司（以下简称"公司"）第八届董 事会第十次会议于2025年4月25日在公司会议室通过现场和通讯相结 合的方式召开。会议通知已于2025年4月15日以书面、传真或电子邮 件等形式向所有董事发出。本次董事会应到董事九名，实到董事九名 （其中：董事王霖先生、张志荣先生，独立董事周德敏先生、邓宏光 先生以通讯方式参加），会议由董事长柯尊洪先生主持，公司监事、 董事会秘书及部分高级管理人员列席了会议。本次会议的召开符合 《中华人民共和国公司法》和《成都康弘药业集团股份有限公司章程》 的有关规定。 成都康弘药业集团股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 会议以书面记名投票及通讯方式表决通过了如下决议： 1. 会议以8票赞成、0票反对、0票弃权审议通过了《二〇二四年 度总裁工作报告》。 总裁柯潇先生回避了本议案的表决。 《二〇二四年度总裁工作报告》于2025年4月26日披露在公 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-012 成都康弘药业集团股份有限公司 关于二〇二四年度利润分配预案的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开的第八届董事会第十次会议和第八届监事会第十次会议审 议通过了《二〇二四年度利润分配预案》，该预案尚需提交公司二〇二 四年度股东会审议。现将相关事宜公告如下： 一、二〇二四年度利润分配预案的审议程序 （一）董事会审议 公司第八届董事会第十次会议审议通过了《二〇二四年度利润分配 预案》，公司董事会同意该利润分配预案并同意将该议案提交公司二〇 二四年度股东会审议。 （二）监事会审议 公司第八届监事会第十次会议审议通过了《二〇二四年度利润分配 预案》，监事会认为该利润分配预案既考虑了对投资者的合理投资回报， 也兼顾了公司的可持续发展，符合公司股东尤其是中小股东的利益，不 存在违反法律、法规和《公司章程》的情形，也不存在损害公司股东特 别是中小股东利益的情形，同意通过该议 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-017 成都康弘药业集团股份有限公司 关于全资子公司吸收合并的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第八届董事会第十次会议，审议通过了《关于全资子 公司吸收合并的议案》。现将相关事宜公告如下： 一、 吸收合并事项概述 为进一步提高公司运营效率、优化资源配置、降低管理成本，公 司全资子公司北京康弘生物医药有限公司(以下简称"北京康弘生物") 拟吸收合并公司全资子公司北京弘健医疗器械有限公司(以下简称 "北京弘健")、公司全资子公司四川康弘中药材种植有限公司(以下 简称"康弘种植")拟吸收合并公司全资子公司成都康弘医药贸易有 限公司(以下简称"成都康贸")、公司全资子公司四川济生堂药业有 限公司(以下简称"济生堂")拟吸收合并公司全资孙公司四川济生堂 兴尚生物科技有限责任公司(以下简称"兴尚生物")。 吸收合并后，北京康弘生物、康弘种植、济生堂存续经营，公司 名称、股权结构保持不变，根据实际经营需求及 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-016 成都康弘药业集团股份有限公司 关于注销2021年股票期权激励计划部分股票期权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第八届董事会第十次会议，审议通过了《关于注销 2021 年股票期权激励计划部分股票期权的议案》。现将有关事项说明如下： 一、 2021 年股票期权激励计划简述及已履行的程序 1、2021 年 6 月 18 日，公司召开第七届董事会第十次会议，审 议通过了《关于公司<2021 年股票期权激励计划（草案）>及其摘要的 议案》《关于公司<2021 年股票期权激励计划考核实施管理办法>的议 案》和《关于提请股东大会授权董事会及其授权人士全权办理 2021 年股票期权激励计划相关事宜的议案》。公司独立董事对该事项发表 了同意的独立意见。 2、2021 年 6 月 18 日，公司召开第七届监事会第七次会议，审 议通过了《关于公司<2021 年股票期权激励计划（草案）>及其摘要的 议案》《 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,198,743,422.58, representing a 9.70% increase compared to ¥1,092,784,087.91 in the same period last year[5] - Net profit attributable to shareholders was ¥400,017,678.69, up 7.09% from ¥373,521,473.06 year-on-year[5] - The basic earnings per share for Q1 2025 was ¥0.43, a 4.88% increase from ¥0.41 in the same period last year[5] - Total operating revenue for the current period reached ¥1,198,743,422.58, an increase of 9.7% compared to ¥1,092,784,087.91 in the previous period[21] - Net profit for the current period was ¥396,624,766.47, representing a 6.8% increase from ¥371,475,098.05 in the previous period[22] - Total comprehensive income amounted to CNY 396,106,074.20, an increase from CNY 370,888,415.97 in the previous period, representing a growth of approximately 6.5%[23] - The company’s total comprehensive income attributable to the parent company was CNY 399,498,986.42, up from CNY 372,934,790.98, representing an increase of approximately 7.1%[23] Cash Flow and Liquidity - The net cash flow from operating activities increased by 6.69% to ¥433,077,896.44, compared to ¥405,935,869.60 in the previous year[5] - The company's cash and cash equivalents increased, contributing to a stronger liquidity position[19] - Cash inflow from sales of goods and services reached CNY 1,208,720,347.20, up from CNY 1,158,201,461.54, marking a growth of approximately 4.3%[25] - The ending balance of cash and cash equivalents was CNY 3,369,779,954.96, an increase from CNY 3,072,565,305.73 in the previous period[26] - The company reported a net increase in cash and cash equivalents of CNY -2,255,647,291.60, compared to CNY -1,597,428,914.87 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,672,737,904.71, reflecting a 3.54% increase from ¥9,341,936,339.67 at the end of the previous year[5] - Total liabilities decreased to ¥627,524,264.95 from ¥695,069,259.77, a reduction of 9.7%[19] - The equity attributable to shareholders of the parent company rose to ¥9,054,671,602.23, compared to ¥8,653,202,130.15, an increase of 4.6%[19] Research and Development - Research and development expenses rose by 47.70% to ¥94,301,139.91, compared to ¥63,845,609.61 in the same period last year, indicating increased investment in R&D[11] - Research and development expenses for the current period were ¥94,301,139.91, up from ¥63,845,609.61, indicating a significant increase of 47.8%[22] - The company has received clinical trial approval for KHN702 from the National Medical Products Administration, indicating progress in its drug development pipeline[15] - The company’s subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received approval for the Phase I clinical trial of KH815 from the Australian Human Research Ethics Committee, showcasing its international research capabilities[15] Shareholder Information - The top shareholder, Chengdu Kanghong Technology Industry Group Co., Ltd., holds a 31.75% stake, indicating strong insider ownership[14] - The second-largest shareholder, Ke Zunhong, owns 22.58% of the shares, further emphasizing significant insider control[14] - The company has a diverse shareholder base, with the top ten shareholders holding a combined total of 80.56% of the shares, indicating concentrated ownership[14] - The company has not reported any changes in the participation of major shareholders in margin trading activities[15] - The company has not disclosed any other significant matters that could impact its financial performance or strategic direction[15] Revenue Breakdown - The revenue from traditional Chinese medicine products was ¥38,411.55 million, showing a 9.71% increase compared to ¥35,012.49 million last year[6] - The revenue from biological drugs increased by 18.56% to ¥64,349.84 million, up from ¥54,274.38 million in the previous year[6] - The company reported a significant increase of 723.00% in other business revenue, reaching ¥102.71 million compared to ¥12.48 million last year[6] Investment Activities - The company holds trading financial assets valued at ¥2,640,000,000.00, indicating a strategic investment in financial instruments[17] - The company reported a net investment loss of ¥134,361.58, compared to a loss of ¥53,158.67 in the previous period[22] - Total cash outflow from investing activities was CNY 2,687,500,476.51, compared to CNY 2,003,173,073.60 in the previous period, reflecting an increase of about 34.2%[26] - The net cash flow from investing activities was negative at CNY -2,687,151,662.15, worsening from CNY -2,003,006,385.60 in the previous period[26]

Financial Performance - The company's operating revenue for 2024 reached ¥4,452,657,799, representing a 12.51% increase compared to ¥3,957,459,641.68 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥1,191,230,760.93, up 14.02% from ¥1,044,765,761.76 in 2023[6]. - The cash flow from operating activities for 2024 was ¥1,411,874,837.73, reflecting a 15.88% increase from ¥1,218,411,128.75 in 2023[6]. - Basic earnings per share for 2024 were ¥1.3, a 14.04% increase from ¥1.14 in 2023[6]. - Total assets at the end of 2024 amounted to ¥9,341,936,339.67, a 9.52% increase from ¥8,529,680,910.70 at the end of 2023[6]. - The total revenue for 2024 reached ¥4,452,657,799, representing a year-on-year increase of 12.51% compared to ¥3,957,459,641.6 in 2023[57]. - The pharmaceutical manufacturing segment contributed ¥4,451,169,730.5, accounting for 99.97% of total revenue, with a year-on-year growth of 12.49%[57]. - The biopharmaceutical product line saw significant growth, generating ¥2,342,687,346.2, which is a 20.98% increase from ¥1,936,471,767.2 in the previous year[57]. - The company achieved a revenue of 445,265.78 million yuan, representing a year-on-year growth of 12.51%[51]. - The net profit attributable to shareholders was 119,123.08 million yuan, with a year-on-year increase of 14.02%[51]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares to all shareholders, based on a total of 919,869,004 shares[3]. - The company distributed a cash dividend of 3.80 RMB per 10 shares, totaling 551,921,402.40 RMB, which represents 100% of the total profit distribution[145][146]. - The board of directors approved a dividend payout of 0.5 RMB per share, reflecting a commitment to returning value to shareholders[127]. Research and Development - The company has completed a product layout focusing on chronic disease prevention and treatment, particularly in hypertension and diabetes[28]. - The company plans to increase investment and research in fields such as ophthalmology, psychiatry/neuroscience, and oncology[28]. - The company focuses on research, manufacturing, and sales of pharmaceutical products and medical devices, maintaining a commitment to innovation and collaboration[33]. - The company has developed key technologies in biopharmaceutical industrialization, synthetic biology, and standardized quality control for traditional Chinese medicine[33]. - The company is developing multiple new drugs, including KH110 for Alzheimer's disease and KH109 for anxiety, both currently in Phase III clinical trials[44]. - The company has ongoing clinical trials for key projects, including KH631 for wet age-related macular degeneration and KH617 for advanced solid tumors[43]. - The company has established a comprehensive R&D system, integrating domestic and international resources for product innovation and technology enhancement[43]. - The company is currently conducting multiple Phase I clinical trials for innovative gene therapies targeting age-related macular degeneration, which are expected to enhance its competitive edge in ophthalmic treatments[67]. - The company is expanding its product pipeline with new indications for existing drugs, enhancing its market position in mental health treatments[68]. - R&D investment rose by 33.57% to approximately ¥604.38 million in 2024, accounting for 13.57% of operating revenue[68]. Market and Competitive Landscape - The innovative drug market in China has exceeded 700 billion RMB in 2023, with expectations to reach 800 billion RMB by 2029, indicating a strong growth trajectory[32]. - The aging population in China presents significant opportunities for the company to address chronic disease treatment, enhancing its market potential[32]. - The competitive landscape in the domestic pharmaceutical market is intensifying, necessitating continuous innovation from local companies to enhance market competitiveness[30]. - The company is actively expanding its international market presence and has secured patents for several first-class new drugs[46]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[122]. Environmental Compliance and Sustainability - The company adheres to numerous environmental protection laws and standards during its operations, ensuring compliance with regulations[162]. - The company has received various environmental approvals for projects, including the solid oral dosage technology transformation and the innovation biological new drug laboratory[163]. - The company has established a comprehensive internal control system to prevent fraud and ensure accurate financial reporting[158]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating its commitment to environmental responsibility[162]. - The company has implemented stringent monitoring protocols for emissions, ensuring that all measured values remain compliant with environmental regulations[171]. - The company continues to monitor and ensure that all emissions remain within regulatory standards, reflecting its commitment to sustainability[176]. - The company has achieved zero occupational disease accidents in 2024, with full coverage of occupational health check-ups and health records for employees[199]. - The company has not experienced any major product quality responsibility accidents in 2024 and has not received confirmed complaints regarding customer privacy violations[200]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholders[108]. - The company is committed to enhancing its value management system and has disclosed plans for valuation improvement[105]. - The company has a structured approach to performance-based incentives for its senior management team[128]. - The company held its annual shareholder meeting on May 16, 2024, with a participation rate of 71.82%[109]. - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including the current chairman who has over 40 years of experience[114]. - The company is focused on maintaining a stable management structure despite the upcoming resignations, ensuring continuity in leadership[112][113]. Employee and Talent Management - The company has established a unique human resource management model to attract and develop talent in R&D, production, and sales[45]. - The number of R&D personnel increased by 4.75% from 569 in 2023 to 596 in 2024[68]. - The company has implemented a comprehensive training program for employees, utilizing various training methods and platforms[143]. - The total number of employees at the end of the reporting period was 4,462[141]. - The company has 406 employees with a master's degree or above, and 1,995 employees with a bachelor's degree[141]. Future Outlook and Strategic Initiatives - The company plans to expand its market presence significantly by 2026, targeting a revenue increase to 264.4 million[111]. - The company aims to enhance its product offerings and technological advancements by 2026, with a focus on innovative drug development[115]. - Future investments will focus on innovative drug development in high-incidence diseases and chronic conditions, leveraging cutting-edge technologies like gene therapy and antibody development[96]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness by 40% in the next six months[126]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product portfolio[115].